Soru

Zorluk: ZorPediatric Infectious Diseases

During morning rounds, the pediatric team evaluates a 1313-month-old male infant who was admitted 4848 hours ago for a febrile urinary tract infection. He has a past medical history of acute lymphoblastic leukemia and is currently receiving maintenance chemotherapy. Upon admission, he was started on empiric intravenous ceftriaxone. Today, he is afebrile and tolerating a regular diet. Urine cultures from admission have grown \textit{Escherichia coli} (>100,000 CFU/mL>100,000 \text{ CFU/mL}) that is resistant to ampicillin but susceptible to cephalexin, ceftriaxone, and trimethoprim-sulfamethoxazole.

Additionally, since yesterday, the patient has developed copious rhinorrhea and a frequent cough. His temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), heart rate is 110/min110/\text{min}, and respiratory rate is 36/min36/\text{min}. Pulse oximetry shows 97%97\% on ambient air. Physical examination reveals clear nasal discharge and diffuse expiratory wheezing bilaterally without intercostal retractions. A viral multiplex polymerase chain reaction panel is positive for respiratory syncytial virus (RSV).

The infant's mother notes he missed his 1212-month wellness visit due to his oncology treatments and requests that all overdue immunizations be administered before he is discharged. She also expresses concern that he is delayed because he only cruises along furniture and cannot yet walk independently without support.

Which of the following is the most appropriate comprehensive management plan for this patient at discharge?

  1. Transition to oral cephalexin, continue supportive care for his respiratory symptoms, withhold live-attenuated vaccines, and reassure the mother regarding his gross motor developmentCevap
  2. B
    Continue intravenous ceftriaxone to complete a 7-day course, continue supportive care for his respiratory symptoms, withhold live-attenuated vaccines, and reassure the mother regarding his gross motor development
  3. C
    Transition to oral cephalexin, prescribe scheduled albuterol nebulizer treatments, withhold live-attenuated vaccines, and reassure the mother regarding his gross motor development
  4. D
    Transition to oral cephalexin, continue supportive care for his respiratory symptoms, administer the measles-mumps-rubella (MMR) vaccine, and reassure the mother regarding his gross motor development
  5. E
    Transition to oral cephalexin, continue supportive care for his respiratory symptoms, withhold live-attenuated vaccines, and refer the patient to early intervention services for physical therapy

Cevap

The correct comprehensive management plan is to transition to oral cephalexin, continue supportive care for his respiratory symptoms, withhold live-attenuated vaccines, and reassure the mother regarding his gross motor development.
The correct management plan synthesizes four distinct clinical decisions optimally. First, in accordance with antimicrobial stewardship, the patient's UTI treatment is stepped down from intravenous ceftriaxone to oral cephalexin, a targeted, narrow-spectrum agent to which the pathogen is susceptible. Second, his new RSV infection is classic bronchiolitis; guidelines strictly recommend against bronchodilators like albuterol in favor of supportive care. Third, despite being overdue for his 12-month immunizations, live-attenuated vaccines (such as MMR and varicella) are strictly contraindicated because he is immunocompromised from leukemia maintenance chemotherapy. Finally, cruising at 13 months represents normal gross motor development (independent walking is expected by 15-18 months), meaning reassurance is indicated rather than a referral for physical therapy.

Adım Adım Çözüm

1
Evaluate the urinary tract infection (UTI) management.
The patient has clinically improved and urine culture susceptibilities are available, showing sensitivity to cephalexin.
Antimicrobial stewardship dictates transitioning from broad-spectrum empiric IV therapy (ceftriaxone) to a narrow-spectrum oral agent once clinical stability and sensitivities allow.
2
Assess the new-onset respiratory symptoms.
The patient has mild RSV bronchiolitis.
Supportive care (e.g., hydration, nasal suctioning) is the mainstay of treatment for bronchiolitis. Bronchodilators (like albuterol) are ineffective and not recommended.
3
Determine immunization eligibility.
The patient is on active maintenance chemotherapy for leukemia.
Live-attenuated vaccines (MMR, varicella) are strictly contraindicated in severely immunocompromised patients due to the risk of uncontrolled vaccine-strain infection.
4
Assess the child's gross motor milestones.
The child is cruising at 13 months.
This is a normal developmental milestone. Independent walking is not considered delayed until a child reaches 15 to 18 months of age, so parental reassurance is appropriate.

Anahtar Kavram

Comprehensive pediatric management requires integrating antimicrobial stewardship, evidence-based supportive care for viral infections, adherence to immunization contraindications in immunocompromised states, and accurate assessment of developmental milestones.
Tahmini Süre:2m 0s
Bu soruyu puanla